TABLE 1.
Patients' characteristics
| Variable |
2019 cohort Total n = 22 |
2020 cohort Total n = 38 |
p‐value for equal population in 2020 and 2019 |
|---|---|---|---|
| Sex; No. (%) | |||
| Male | 11 (50%) | 22 (57.9%) | .599 $ |
| Female | 11 (50%) | 16 (42.1%) | |
| Age | |||
| No. (%), mean, [±SD]; | 64.95 [±19.52]; | 53.53 [±20.19]; | .037 § |
| Median {range; interquartile range} | 66.50 {18–90; 24} | 55.50 {15–84; 30} | .026* |
| Presence of active or recent infectious symptoms; No. (%) | |||
| No | 20 (90.90%) | 30 (78.90%) | .299 $ |
| Yes | 2 (9.10%) | 8 (21.10%) | |
| Days from onset to seeking medical attention | |||
| No. (%), mean, [±SD]; | 0.55 [±0.51]; | 1.68 [±1.64]; | .003 § |
| Median, {range; interquartile range} | 1.00 {0–1; 1} | 1.00 {0–7; 1} | .001* |
| Diabetes; No. (%) | |||
| No | 15 (68.20%) | 30 (78.90%) | .372 $ |
| Yes | 7 (31.80%) | 8 (21.10%) | |
| Autoimmune diseases; No. (%) | |||
| No | 21 (95.50%) | 35 (92.10%) | 1.000 $ |
| Yes | 1 (4.50%) | 3 (7.90%) | |
| Immunosuppressive therapy; No. (%) | |||
| No | 21 (95.50%) | 37 (97.40%) | 1.000 $ |
| Yes | 1 (4.50%) | 1 (2.60%) | |
| Prescription for steroid treatment; No. (%) | |||
| No | 3 (13.60%) | 7 (18.40%) | .732 $ |
| Yes | 19 (86.40%) | 31 (81.60%) | |
$
p‐value for Fisher exact distribution.
§
p‐value for Student's t‐distribution.
*
i‐value for U statistic.